profit from every $100 of sales.
$0$100
Prestige Consumer Healthcare
$46.19+1.92% today
-23.0% in 1 year
1-year low $42.981-year high $70.21
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay $11.50 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Prestige Consumer Healthcare sold, what it kept, and what it did with the cash.
Sales went from $1.13 billion in 2023 to $1.09 billion in 2026, with $190 million of profit last year.
SalesProfit
Prestige Consumer Healthcare handed back 63% of the cash it generated last year.
Buybacks $156M
Free cash flow 2026$246M
Bought back its own shares$156M
Paid as dividends–
Cash vs. debt$64M vs. $1.0B
Prestige Consumer Healthcare vs. similar companies
Prestige Consumer Healthcare grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Prestige Consumer Healthcare | 11.5× · Cheap | ||
 Great Elm Group | 5.2× · Cheap | ||
 Accendra Health | No profit yet | ||
 Wellgistics Health | No profit yet | ||
 Synergy CHC | No profit yet |
AI analysis
An AI analyst reads Prestige Consumer Healthcare's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 1,128 | 1,125 | 1,138 | 1,089 | |
| 625 | 624 | 634 | 596 | |
| 348 | 342 | 349 | 309 | |
| 8 | 374 | 362 | 331 | |
| -82 | 209 | 215 | 190 | |
| -1.65 | 4.17 | 4.29 | 3.91 | |
| 55.4% | 55.5% | 55.8% | 54.7% | |
| 30.8% | 30.4% | 30.7% | 28.4% | |
| -7.3% | 18.6% | 18.9% | 17.5% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 3,354 | 3,318 | 3,402 | 3,494 |
| Cash | 58 | 46 | 98 | 64 |
| Total debt | 1,367 | 1,140 | 1,044 | 1,045 |
| Total liabilities | 1,907 | 1,663 | 1,567 | 1,607 |
| 1,447 | 1,655 | 1,835 | 1,888 | |
| 50 | 50 | 50 | 49 | |
| -0.7% | 9.7% | 9.1% | 8.1% | |
| -5.7% | 12.6% | 11.7% | 10.1% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 230 | 249 | 252 | 258 | |
| 8 | 10 | 8 | 11 | |
| 222 | 239 | 243 | 246 | |
| Dividends paid | – | – | – | – |
| 50 | 25 | 52 | 156 | |
| 12 | 14 | 11 | 11 |
Valuation
- 11.5×
- 9.6×
- –
- 1.2×
- 2.0×
- 8.9×
- 9.6×
- 11.3%
- 8.7%
- 0.0%
Profitability
- 54.7%
- 28.4%
- 17.5%
- 30.3%
- 6.8%
- 5.0%
- 10.3%
- 5.4%
- 9.2%
- –
Growth
- −1.2%
- –
- +4.5%
- –
- −0.9%
Financial health
- 3.0×
- 0.03
- 1.4%
- 7.3×
- 3.57
- 2.25
- 0.31
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 44%of 952
Top 10%of 884
Top 14%of 601
Bottom 16%of 886
Top 6%of 987
What analysts expect
- Average price target
- $66.00
- Range
- $66.00 – $66.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | 1.23 | 1.39 | −11.5% |
| Feb 5, 2026 | 1.14 | 1.16 | −1.7% |
| Nov 6, 2025 | 1.07 | 0.97 | +10.3% |
| Aug 7, 2025 | 0.95 | 1.01 | −5.9% |
| May 8, 2025 | 1.32 | 1.30 | +1.5% |
| Feb 6, 2025 | 1.22 | 1.16 | +5.2% |
| Nov 7, 2024 | 1.09 | 1.08 | +0.9% |
| Aug 8, 2024 | 0.90 | 0.86 | +4.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
58No pass
Benjamin Graham
76Pass
Philip Fisher
61Pass
Peter Lynch
56No pass
Joel Greenblatt
46No pass
Charlie Munger
58No pass
Terry Smith
51No pass
Questions about Prestige Consumer Healthcare
Is Prestige Consumer Healthcare a good stock to buy?
A solid business, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Prestige Consumer Healthcare AI analysis
What does Prestige Consumer Healthcare do?
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. It is in Medical - Distribution.
Does Prestige Consumer Healthcare pay a dividend?
No. Prestige Consumer Healthcare does not pay a dividend at the moment; in 2026 it returned $156 million to shareholders by buying back its own shares.
Is Prestige Consumer Healthcare stock halal?
No. Prestige Consumer Healthcare does not pass our halal screen: its debt is 48% of its market value, at or above the 33% limit. How we check
How has Prestige Consumer Healthcare stock done over the past year?
Down 23.0% over the past twelve months, to $46.19. It traded between $42.98 and $70.21 and is 34.2% below its high.
Who are Prestige Consumer Healthcare's competitors?
The largest listed companies in the same industry are Great Elm Group, Accendra Health, Wellgistics Health and Synergy CHC. The peers table on this page compares their profit, growth and price with Prestige Consumer Healthcare's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.